Carbamazepine as a First-Line Treatment

Indications and Efficacy

• The American Academy of Neurology recommends carbamazepine as a first-line treatment for trigeminal neuralgia, with 70% of patients showing partial or complete pain relief in controlled studies 1
• Approximately 97% of patients with paroxysmal kinesigenic dyskinesia (PKD) respond to carbamazepine/oxcarbazepine 2, 3

Dosage and Administration

• The initial dose for trigeminal neuralgia is 200 mg at night, with a gradual increase of 200 mg every 7 days 1
• The final dose for trigeminal neuralgia is 400-1200 mg/day, divided into 2-3 doses 1
• The recommended initial dose for PKD is 50 mg, with more than 85% of patients achieving complete remission with low doses (50-200 mg/day) 2, 4

Safety and Precautions

• The most common adverse effects are somnolence, headache, and dizziness 1
• Carbamazepine can cause severe skin reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, especially in the Han Chinese population 2
• It is recommended to perform an HLA-B*15:02 test before starting treatment to reduce the risk of adverse skin reactions 2, 4

Special Considerations

• In pregnancy, a comprehensive risk-benefit assessment should be performed before conception 2, 4
• For patients with mild manifestations, consider discontinuing therapy before or during pregnancy due to fetal risk 2, 4